dr. edith perez on a phase iii trial comparing eribulin and capecitabine
Published 11 years ago • 358 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
2:13
dr. edith perez on study 301 that compared eribulin to capecitabine in mbc
-
1:36
dr. chris twelves compares eribulin and capecitabine
-
1:04
dr. edith perez discusses the adjuvant treatment of breast cancer
-
1:06
dr. edith perez on the antibody-drug conjugate t-dm1
-
1:07
dr. edith perez discusses bolero-1 trial results for her2-positive breast cancer
-
4:48
fda approves ribociclib (kisqali) for stage 2-3 hr /her2- breast cancer at higher risk of recurrence
-
1:00:06
metastatic breast cancer forum 2018: er breast cancer | dana-farber cancer institute
-
4:33
the her pathway and cancer
-
1:20
dr. edith perez on the etirinotecan pegol for her2-negative breast cancer
-
0:47
dr. edith perez on adjuvant treatments
-
1:25
dr. edith perez on immune checkpoint inhibition in triple-negative breast cancer
-
1:38
dr. william gradishar discusses the eribulin and capecitabine 301 study
-
1:03
dr. edith perez describes the mayo clinic breast cancer translational genomics program
-
3:07
dr. edith perez on the development of targeted therapies
-
1:08
dr. edith perez on her anticipated results for asco and sabcs
-
1:26
dr. spigel discusses results from a phase iii study exploring eribulin in nsclc
-
1:15
dr. edith perez discusses adjuvant chemotherapy patient selection
-
7:28
edith a. perez, md: anti-her2 therapies
-
4:12
eribulin in recurrent metastatic er breast cancer
-
16:17
dr. edith perez discusses anti-her2 therapies -- 2012 sabcs
-
2:08
dr. joyce o'shaughnessy on eribulin in metastatic breast cancer
-
1:24
dr. perez discusses the bolero-2 everolimus trial